Canagliflozin approved by NICE for diabetes

NICE has approved canagliflozin (Invokana) for use in dual and triple therapy and in combination with insulin in type II diabetes.

Canagliflozin (Invokana) prevents glucose reabsorption in the kidneys and increases urinary glucose excretion to lower blood glucose levels
Canagliflozin (Invokana) prevents glucose reabsorption in the kidneys and increases urinary glucose excretion to lower blood glucose levels

Janssen-Cilag launched canagliflozin in March for use as monotherapy or in combination with other hypoglycaemics and/or insulin when the existing regimen, in combination with diet and exercise changes, provides inadequate glycaemic control.

The guidance accepts canagliflozin for use in combination with metformin when sulfonylureas are contraindicated or not tolerated or if the patient is at significant risk of hypoglycaemia or its consequences. The SGLT2 inhibitor is also recommended as an option for combination therapy with insulin, with or without other hypoglycaemics.

In addition, canagliflozin can be used on the NHS in a triple oral therapy regimen with metformin plus either a sulfonylurea or a thiazolidinedione ('glitazone'). This differs from the NICE recommendations for dapagliflozin published in June 2013, where the regulatory body rejected dapagliflozin for use in triple oral regimens.

A fixed-dose combination tablet containing canagliflozin and metformin has been approved in the EU but has not yet been launched in the UK.

NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes (TA315)

Follow MIMS on Twitter


Read these next

SGLT2 inhibitors: risk of diabetic ketoacidosis

SGLT2 inhibitors: risk of diabetic ketoacidosis

Patients receiving SGLT2 inhibitors (canagliflozin,...

Xultophy: first insulin/incretin mimetic combination launched

Xultophy: first insulin/incretin mimetic combination launched

Xultophy is a prefilled pen containing a fixed-ratio...

Vokanamet: new combination oral hypoglycaemic

Vokanamet: new combination oral hypoglycaemic

Janssen-Cilag has launched a twice-daily fixed dose...

Jardiance: further SGLT2 inhibitor option available

Jardiance: further SGLT2 inhibitor option available

Boehringer Ingelheim has launched Jardiance (empagliflozin),...

Xigduo (dapagliflozin + metformin): first SGLT2 inhibitor combination tablet

Xigduo (dapagliflozin + metformin): first SGLT2 inhibitor combination tablet

Xigduo (dapagliflozin + metformin) has been launched...

Invokana: new SGLT2 inhibitor for type II diabetes

Invokana: new SGLT2 inhibitor for type II diabetes

Janssen-Cilag has launched Invokana (canagliflozin)...

NICE approval for new overactive bladder and diabetes drugs

NICE approval for new overactive bladder and diabetes drugs

First-in-class treatments for overactive bladder and...

Forxiga: first in new class of diabetes treatments

Forxiga: first in new class of diabetes treatments

The SGLT2 inhibitor dapagliflozin (Forxiga) has been...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.